NAB has gathered a world class management team with extensive expertise and a successful track record in drug development, commercialization, and asset management of cancer immunotherapies (monotherapy as well as combinations and ADCs), reformulation, and orphan drug development. All our C- Suite leaders have medical training, and leaders in their respective departments. The entire leadership of NAB are industry seasoned females, MDs, and of the highest professional caliber in their class. An all-female, private company, with no current debt, owns its robust IP with the proven track record in human trials, with the support of the opinion leaders of the respective therapeutic areas. A value driven organization with serving the patients as its only mission.
Arial(Nepton) Sheikh- Khoni, MD (Chief Executive Officer)
Arial (Nepton) is a trained medical doctor (MD) in Internal Medicine and Research Fellowship in Medical Oncology with more than 14 years of clinical experience. She also has an intimate knowledge and understanding of clinical research and development as well as global regulatory environment with more than 8 years of industry experience in clinical development, regulatory affairs, global safety and pharmacovigilance. She has held positions in clinical development, global pharmacovigilance and regulatory as a student fellow all the way post her clinical training in medicine in many aspects of drug development arena. Her care for patients, passion for clinical development and advancement of science made her to be the right choice as the CEO of Nexus Alliance Biopharma in 2018.
Ghazaleh Shoja E Razavi, MD (Chief Medical Officer)
Ghazaleh is a practicing hematologist, medical oncologist with more than ten years of clinical experience. She also has a deep knowledge and understanding of pharmaceutical environment with more than five years industry experience in safety, pharmacovigilance, medical affairs as well as designing and monitoring of clinical trials in active immunotherapy, immune-oncology and novel chemo and targeted anti-cancer agents. She has been graduated from medical school in 1997, board certified in internal medicine in 2002 and board certified in hematology and medical oncology in 2006. She has also trained in supportive and palliative care in Italy, granted by European Society for Medical Oncology (ESMO) in 2007 and completed her clinical fellowship in malignant hematology and stem cell transplant in Canada in 2017.